MedTech Strategist Issue: Vol. 6, No. 3 - February 20, 2019

 

Already a Subscriber?

 

Not a Subscriber?


Obesity - “Will Allurion’s Gastric Balloon Platform Grow the Obesity Market?”

By Mary Stuart, Senior Writer/Market Analyst

Device companies haven’t yet brought forward the right interventions to help the obesity market reach its enormous potential. With a “procedureless” medical implant that’s supported by a connected health device and app for ongoing patient support, young company Allurion appears to have the formula for success.

Obesity.jpeg

Innogest.jpg

Venture Capital - “Innogest and the Virtues of Focused Investing”

By David Cassak, Co-Editor-in-Chief

Most venture capital firms like to mitigate risk by having a diversified portfolio, taking an opportunistic approach to clinical and technology spaces. But Innogest, one of the most active medtech investors around today, is betting on a strategy focused on cardiovascular, with an incubator to supplement its efforts.


Precision Medicine - “OpGen’s Bet on Precision Antibiotics”

By Wendy Diller, Senior Writer/Market Analyst

The journey of OpGen, founded by some heavy hitters in diagnostics, illustrates how much the once-staid field of microbiology is changing and also demonstrates the challenges of applying big-data science and digital approaches to precision medicine initiatives.

Opgen.jpg

Clinical Diagnostics - “Magnolia Medical: A Simple Solution With a Big Impact on Blood Draw Contamination”

By Wendy Diller, Senior Writer/Market Analyst

Magnolia’s solution to one of the most pernicious, yet overlooked flaws in infectious disease testing, sample contamination during the collection process, is an inexpensive, mechanical device that keeps skin fragments colonized with bacteria from entering a blood sample.


Sleep Disorders - “NightWare: Putting Nightmare Disorder to Rest”

By Colin Miller, Contributing Writer

Because prescription sleep aids can interact with other drugs, and many nightmare disorder patients are likely to be prescribed at least one drug, the less chemical the treatment the better. NightWare serves that need with an Apple Watch-based application that senses when a nightmare occurs and disrupts the episode with minimal stimulation to preserve sleep through the night.

megan-te-boekhorst-1116023-unsplash.jpg

Not a Subscriber?

Already a Subscriber?

Want a Sample Article?


Companies Covered in this Issue: Allurion Technologies Inc., Anaconda Biomed SL, Angiodroid SRL, Apollo Endosurgery Inc., BARONova Inc.,  bioMerieux Inc., EryDel SPA, Fjord Ventures, Innogest Capital,  Livongo Health,  Luminex Corp., Magnolia Medical Technologies,  MedLumics SL, MD Start, Medtronic PLC, Merck & Co. Inc., Newronika SRL, NightWare Inc., Obalon Therapeutics Inc., Omada Health Inc.,  OpGen Inc., Pi-Cardia Ltd., Qiagen NV, ReShape Life Sciences Inc., Teleflex Inc., The Foundry; Thermo Fisher Scientific Inc.

Topics Covered in this Issue: Aesthetics/Dermatology; Cardiovascular/Vascular; Critical Care/Emergency Medicine; Diagnostics; Digital Health; Gastroenterology; Investors & Dealmaking; Neurology/Neurovascular; Start-Ups to Watch